Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.71 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1794544 | 0.98 | CYP4A11 (0.69) | CYP4A11CYP4F2HSD17B10MAPTRXFP1 | |
| SCHEMBL4199917 | 0.95 | CYP4A11 (0.70) | CYP4A11CYP4F2HSD17B10MAPTRXFP1 | |
| Adipic Acid SCHEMBL17103029 | 0.89 | POLB (0.66) | CYP4A11CYP4F2HSD17B10MAPTPOLB | |
| SCHEMBL661620 | 0.88 | CYP4A11 (0.64) | CYP4A11CYP4F2HSD17B10MAPTPOLB | |
| Sebacic Acid SCHEMBL10790215 | 0.88 | POLB (0.64) | CYP4A11CYP4F2MAPTPOLBLOXL2 | |
| SCHEMBL10939883 | 0.88 | POLB (0.64) | CYP4A11CYP4F2MAPTPOLBLOXL2 | |
| SCHEMBL10641751 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2HSD17B10MAPTLOXL2 | |
| SCHEMBL18158250 | 0.85 | CYP4A11 (0.69) | CYP4A11CYP4F2HSD17B10MAPTLOXL2 | |
| SCHEMBL10661898 | 0.85 | CYP4A11 (0.69) | CYP4A11CYP4F2HSD17B10MAPTLOXL2 | |
| SCHEMBL19889904 | 0.85 | CYP4A11 (0.69) | CYP4A11CYP4F2HSD17B10MAPTLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304525-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-10-20 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | CYP4A11 1144/4885CYP4F2 2199/4885HSD17B10 358/4885 |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CYP4A11 2075/4885CYP4F2 3308/4885HSD17B10 4072/4885 |
| US-20160304525-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, TUBB1, TUBA1C | CYP4A11 3976/4885CYP4F2 2082/4885HSD17B10 4351/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CYP4A11 2075/4885CYP4F2 3308/4885HSD17B10 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.